Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Beauchamp LM, Orr GF, De Miranda P, Bumette T, Kre-nitsky TA (1992) Antiviral Chem Chemother 3:157–164
Krenitsky TA, Beauchchamp LM (1989) Eur Pat Appl, zit. nach CA 112:112048
De Miranda P, Burnette TC (1994) Drug Metab Dispos 22:55–59
Burnette TC, De Miranda P (1994) Drug Metab Dispos 22:60–64
Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Pos-ner J (1995) Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 39:2759–2764
Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ (1995) Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immuno-competent adults. Antimicrob Agents Chemother 39:1546–1553
Perry CM, Faulds D (1996) Valaciclovir. A review of its antiviral acitivity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 52:754–772
Glaxo Wellcome, Hoechst (1995) Fachinformation Valtrex
Stahlmann R, Chahoud I, Thiel R, Klug S, Förster C (1997) The developmental toxicity of three antimicrobial agents observed only in nonroutine animal studies. Reprod Toxicol 11:1–7
Bialer M, Haj-Yehia A, Barzaghi Pisani F, Perucca E (1990) Pharmacokinetics of a valpromide isomer, valnoc-tamide, in healthy subjects. Eur J Clin Pharmacol 38:289–291
Haj-Yehia A, Bialer M (1988) Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. J Pharm Sci 77:831–834
Pisani F, Fazio A, Artesi C, Oteri G, Spina E, Tomson T, Perucca E (1992) Impairment of carbamazepine-10,11-ep-oxide elimination by valnoctamide, a valpromide isomer, in healthy subjects. Br J Clin Pharmacol 34:85–87
Verheij AA (1992) Coma door overdosering van valnoctamide. Ned Tijdschr Geneeskd 1992 Jun 13; 136(24): 1177
Melissant CF, Vinks AA, Sleeboom HP (1992) Coma door overdosering van valnoctamide. Ned Tijdschr Geneeskd 136:793–794
Freifelder M, Geiszier A, Stone G (1961) J Org Chem 26:203
Bühlmayer P, Furet P, Criscione L, De Gasparo M, Whitebread S, Schmidlin T, Lattmann R, Wood J (1994) Bioorg Med Chem Lett 4:29–34
Criscione L, Bradley WA, Bühlmayer P, Whitebread S, Glazer R, Lloyd P, Mueller P, De Gasparo M (1995) Car-diovasc Drug Rev 13:230–250
Waldmeier F, Flesch G. Müller P, Winkler T, Kriemler HP, Bühlmayer P, De Gasparo M (1997) Xenobiotiea 27:59–71
Sioufi A, Marfil F, Godbillon J (1994) J Liq Chromatogr 17:2179–2186
Burell LM, Johnston CI (1997) Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. Drugs and Aging 10:421–434
Criscione L, De Gasparo M, Bühlmayer P, Whitebread S, Ramjoue HPR, Wood J (1993) Pharmacological profile of valsartan: a potent orally active, nonpeptide antagonist of the angiotensin II ATI-receptor subtype. Br J Pharmacol 110:761–771
Yamamoto S, Hayashi N, Kometani M, Nakao K (1997) Pharmacological profile of valsartan, a non-peptide angiotensin II typ 1 receptor antagonist. 5thcommunication: hemodynamic effects of valsartan in dog heart failure models. Arzneimittel-Forschung 47:630–634
De Gasparo M, Whitebread S (1995) Binding of valsartan to mammalian angiotensin ATI receptors. Regulatory peptides 59:303–311
Markham A, Goa KL (1997) Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 54:299–311
Zierhut W, Laurent D, Allegrini P, Bullock G, Cumin F, Whitebread S, De Gasparo M (1994) Comparison of the effects of angiotensin converting enzyme inhibition and ATI-blockade of left ventricular structure and functional in renal hypertensive rats as determined by magnetic resonance imaging. Eur Heart J 15(Suppl):428
Black HR, Graff A, Shute D, Stoltz R, Ruff D, Levine J, Shi Y, Mallows S (1997) Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-coverting enzyme inhibitor, lisinopril. J Human Hypertension 11:483–489
Flesch G, Müller P, Lloyd P (1997) Absolute bioavaila-bility and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 52:115–120
Bindschedler M, Degen P, Flesch G, De Gasparo M, Preiswerk G (1997) Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furose-mide. Eur J Clin Pharmacol 52:371–378
Czendlik CH, Sioufi A, Preiswerk G, Howald H (1997) Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol. Eur J Clin Pharmacol 52:451–459
Jung F, Kuy L, Poethke W, Pohloudek-Fabini R et al. (1969) Kommentar zum Deutschen Arzneibuch, 7. Ausgabe, Bd. VI, Akademieverlag, Berlin
Bricout J (1978) Ann Nutr Aliment 32:947–955, zit. nach CA (1979) 90:136161
Thielemann H (1980) Sci Pharm 48:389–390
Packler KGR, Matlok F, Gremiich HU (1988) Merck FT-IR Atlas, VCH Verlagsgesellschaft, Weinheim, S. 607
Drugs Fut (1988) 13(9):839-840
Schweizer E, Thielen RJ, Frazer A (1997) Exp Opin luvest Drags 6:65–78
Holliday SM, Benfield P (1995) Drugs 49:280–294
Morton WA, Sonne SC, Verga MA (1995) The Annals of Pharmacotherapie 29:387–395
Andrews JM, Ninan PT, Nemeroff CB (1996) Depression 4:48–56
Thase ME (1996) J Clin Psychopharmacol 16 (Suppl 2):10S–18S
Kelsey JE (1996) J Clin Psychopharmacol 16 (Suppl 2):21S–26S
Ballenger JC (1996) J Clin Psychpharmacol 16 (Suppl 2):29S–35S
Ereshefsky L (1996) J Clin Psychopharmacol 16 (Suppl 2):37S–50S
Rudolph RL, Derivan AT (1996) J Clin Psychopharmacol 16(Suppl 2):54S–59S
Ellingrod VL, Perry PJ (1994) Am J Hosp Pharm 51:3033–3046
Goldberg RJ (1997) Drags-Aging 11:119–131
Dierick M (1997) Eur Psychiatry 12 (Suppl 4):307–313
Preskorn S (1997) Eur Psychiatry 12 (Suppl 4):285–294
Dinan TG, Burnett F (1997) J Serotonin Res 3/4:203–221
Scott MA, Shelton PS, Gattis W (1996) Pharmakotherapie 16:352–365
Rickeis K, Derivan A, Entsuah R, Miska S, Rudolph R (1995) Depression 3:146–153
Taft DR, Lyer GR, Behar L, DiGregorio RV (1997) Drag Metab Dispos 25:1215–1218
Malizia AL, Melichar JM, Brown DJ, Gunn RN, Reynolds A, Jones T, Nutt DJ (1997) J Psychopharmacol 11:279–281
Ball SE, Ahern D, Scatina J, Kao J (1997) Br J Clin Pharmacol 43:619–626
Salin-Pascual RJ, Moro-Lopez ML (1997) Psychophar-makologie 129:295–296
Shrivastava RK, Cohn C, Crowder J, Davidson J, Dunner D, Feighner J, Kiev A, Patrick R (1994) J Clin Psychopharmacol 14:322–329
Troy SM, Schultz RW, Parker VD, Chiang ST, Blum RA (1994) Clin Pharmacol Ther 56:14–21
Tominaga N, Yo E, Ogawa H, Yamashita S, Yabuuchi Y, Nakagawa K (1984) Chem Pharm Bull 32:2100–2110
Shimizu T, Osumi T, Niimi K, Nakagawa K (1984) Arz-neim Forsch 34:334–341
Rapundalo ST, Lathrop DA, Harrison SA, Beavo JA, et al. (1988) Cyclic AMP-dependent and cyclic AMP-Indepen-dent actions of a novel cardiotonic agent, OPC-8212. Nau-nyn Schmiedebergs Arch Pharmacol 338:692–698
Yatani A, Imoto Y, Schwartz A, Brown AM (1989) New positive inotropic agent OPC-8212 modulates single Ca2+ Channels in ventricular myoeytes of guinea pig. J Cardio-vasc Pharmacol 13, 812–819
Lathrop DA, Nanasi PP, Schwartz A, Varro A (1993) Ionic basis for OPC-8212-induced increases in action potential duration in isolated rabbit, guinea pig and human ventricular myocytes. Eur J Pharmacol 240:127–137
Packer M (1993) The development of positive inotropic agents for chronic heart failure: have we gone astray? J Am Cardiol 22 (4 Suppl A):119A–126A
Itoh H, Kusagawa M, Shimomura A, Suga T, et al. (1993) Ca2+(-)dependent and Ca2+(-)independent vasorelaxati-on induced by cardiotonic phosohodiesterase inhibitors. Eur J Pharmacol 240:57–66
Asanoi H, Sasyama S, Kameyama T, Ishizaka S, et al. (1989) Sustained inotropic effects of a new cardiotonic agent OPC-8212 in patients with chronic heart failure. Clin Cardiol 12:133–138
OPC-8212 Multicenter Research Group (1990) A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. Cardio-vasc Drugs Ther 4:419–425
Katz AM (1995) Cell death in the failing heart: role of an unnatural growth response to overload. Clin Cardiol 18(9 Suppl 4):IV36–IV44
Shioi T, Mastsumori A, Matsui S, Sasayama S (1994) Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and mon-cytic cell line. Life Sci 54:PL11–PL16
Matsumori A, Shioi T, Yamada T, Matsui S (1994) Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 89:955–958
Oyaizu N, McCloskey TW, Than S, Pahwa S (1996) Inhibition of CD4 cross-linking-induced lymphocytes apop-tosis by vesnarinone as a novel immunomodulating agent: vesnarinone inhibits Fas expression and apoptosis by blocking cytokine secretion. Blood 87:2361–2368
Sato Y, Matsumori A, Sasayama S (1995) Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells. J Mol Cell Cardiol 27:2265–2273
Matsui S, Matsumori A, Matoba Y, Uchida A, et al. (1994) Treatement of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production. J Clin Invest 94:1212–1217
Hattori Y, So S, Hattori S, Kasai K, et al. (1995) Vesnarinone inhibits induction of nitric oxide synthase in J774 macrophages and rat cardiac myocytes in culture. Cardio-vasc Res 30:187–192
Feldman AM, Baughman KL, Lee WK, Gottlieb SH, et al. (1991) Usefulness of OPC-8212, a quinolinone derivate, for chronic congestive heart failure in patients with ischemic heart diesase or idiopathic dilated cardiomyopathy. Am J Cardiol 68:1203–1210
Feldman AM, Bristow MR, Pamly WW, Carson PE, et al. (1993) Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med 329:149–155
Nony P, Boissel JP, Lievre M, Leizorovicz A, et al. (1994) Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analy-sis. Eur J Clin Pharmacol 46:191–196
Baughman K (1995) New medical therapies for advanced left ventricular dysfunction. Cardiol Clin 13:27–34
Miyamoto G, Sasabe H, Tominaga N, Uegaki N, et al. (1988) Metabolism of a new positive inotropic agent, 3,4-dihy dro-6-[4-(3,4-dimethoxybenzoy 1)-1-piperaziny 1]-2(lH)-quinoline (OPC-8212) in rat, mouse, dog, monkey and human. Xenobiotica 18:1143–1155
Ohnishi A, Ishizaki T (1988) Pharmacokinetic profile of OPC-8212 in humans: a new, nonglycoside, inotropic agent. J Clin Pharmacol 28:719–726
Furusawa S, Ohashi Y, Asanoi H (1996) Vesnarinone-in-duced granulocytopenia: incidence in Japan and recommendations for safety. J Clin Pharmacol 36:477–481
Bertolet BD, White BG, Pepine CJ (1994) Neutropenia occuring during treatment with vesnarinone (OPC-8212). Am J Cardiol 74:968–970
Uetrecht JP, Zahid N, Whiltfield D (1994) Metabolism of vesnarinone by activated neutrophils: implications for vesnarinone-induced agranulocytosis. J Pharmacol Exp Ther 270:865–872
Uetrecht JP (1995) Myeloperoxidase as a generator of drug free radicals. Biochem Soc Symp 61:163–170
Mar31, S. 102
Drugs Fut (1984) 9(4):283-284
Araki T, Kato H, Nagaki S et al (1997) Mech Ageing Dev 95:13–29
Araki T, Kogure K (1989) Mol Chem Neuropath 11:33–43
Lörincz C, Szasz K, Kisfaludy L (1976) Arzneim Forsch 26:1907
Kuge Y (1994) Synth Commun 24:759
Kiss B, Karpati E (1996) Acta Pharm Hung 66:213–24
Quevauviller A et al (1966) Ann Pharm Fr 24:39–41
Woodward RB et al. (1945) J Am Chem Soc 67:860–875
Cosnier D, Cheucle M, Rispat G, et al. (1977) Influence of hypercapnia on the cerebrovascular activities of some drugs in the treatment of cerebral ischemia. Arzneimittelf. 27:1566–1569
Hünermann B, Felix R, Wesener K, et al. (1973) Einfluß von Viquidil auf die Hirnzirkulation. Arzneimittelf. 23:1074–1076
Mar 31, S. 1767
Uzan A, Guérémy C (1972) Viquidil: étude du métabolisme par méthode isotopique. II. Arzneimittelf. 22:1341–1346
Uzan A, Guérémy C (1974) Viquidil: étude du métabolisme par méthode isotopique. III. Arzneimittelf. 24:34–39
Prous J, Graul A, Castaner J (1994) Drugs Fut 19:457–459
Raeymaekers AHM, Freyne EJE, Van Gelder JLH, Verier MG (Janssen Pharm NV) AU 8816537, EP 293978, JP 88316775, zit. nach Lit. 1
Johnston SR, Smith IE, Doody D, Jacobs S, Robertshaw H, Dowsett M (1994) Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res 54(22):5875–5881
De Coster R, Tuman RW, Bowden CR, Bruynseels J, Vanderpas H, Van Rooy P, Anery WK, Janssen PA (1989) Aromatase inhibition by R 76713: experimental and clinical pharmacology. J Steroid Biochem 34(1–6):427–430
Wouters W, Snoeck E, De Coster R, Vorozole (1994) A specific nonsteroidal aromatase inhibitor. Breast Cancer Res Treat 30(1):89–94
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
von Bruchhausen, F. et al. (1999). V. In: von Bruchhausen, F., et al. Hagers Handbuch der Pharmazeutischen Praxis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-58388-9_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-58388-9_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63569-4
Online ISBN: 978-3-642-58388-9
eBook Packages: Springer Book Archive